Wednesday, December 13, 2017
 
 
Company News: Page (1) of 1 - 04/21/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations By PR Newswire This article is no longer available,but here are some related topics.


Page: 1


 





About Video Based Tutorials - Contact Us - Advertise With Us - Privacy Guidelines